Intrathecal grafting of unencapsulated adrenal medullary tissue can bring CD4 T lymphocytes into CSF: a potentially deleterious event for the graft.
Adrenal medullary tissue including chromaffin cells was grafted intrathecally in cancer patients to relieve intractable pain. The central nervous system (CNS) is considered an immune privileged site. Therefore, non-HLA-matched and unencapsulated tissue was grafted in 15 patients and 1 sham control in a series of at least 20 grafts. We observed an increase in CSF lymphocyte counts in 15/20 allografts (75%). In contrast to peripheral blood, CD4 T cells predominated in the CSF, but failed to exhibit an activated phenotype (CD25+ CD45RO+ HLA-DR+). The positive effect of graft on pain, the high met-enkephalin levels, the absence of any increase in CSF cytokine levels particularly for IFN-gamma or IL-2 (but not IL-10 and IL-6), indirectly indicated that the graft was tolerated despite the presence of CSF lymphocytes. The single treatment failure and three of four cases of partial efficacy occurred in grafts where CSF lymphocytes were present. Moreover, when assayed (n = 7), the CD4+ CSF lymphocytes still retained the capacity to exhibit ex vivo a normal or enhanced frequency of T CD4 cells producing IFN-gamma and IL-2. Taken together, our observations indicate that impairment of the local immunosuppressive balance can lead to activation of those CSF CD4 T cells and drive a rejection process. This study suggests further work on the purification and/or the immunoisolation of tissues grafted in the CNS will be necessary, particularly when the possibility of long-term and repeated grafting is considered.
Tkaczuk
J
J
Immunology Department, Rangueil Hospital, and Rangueil Medical School, Paul Sabatier University, Toulouse, France. tkaczuk@cict.fr
Bes
J C
JC
Duplan
H
H
Sallerin
B
B
Tafani
M
M
Charlet
J P
JP
Abbal
M
M
Lazorthes
Y
Y
Ohayon
E
E
D000313:Adrenal Medulla / Q000166:cytology* / Q000637:transplantation; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology* / Q000276:immunology / Q000378:metabolism; D002465:Cell Movement / Q000276:immunology*; D002470:Cell Survival / Q000276:immunology; D002555:Cerebrospinal Fluid / Q000166:cytology / Q000276:immunology; D019439:Chromaffin Cells / Q000637:transplantation*; D004744:Enkephalin, Methionine / Q000134:cerebrospinal fluid; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D007278:Injections, Spinal; D007371:Interferon-gamma / Q000134:cerebrospinal fluid; D016753:Interleukin-10 / Q000134:cerebrospinal fluid; D007376:Interleukin-2 / Q000134:cerebrospinal fluid; D015850:Interleukin-6 / Q000134:cerebrospinal fluid; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D016212:Transforming Growth Factor beta / Q000134:cerebrospinal fluid
D000701:Analgesics, Opioid; D007376:Interleukin-2; D015850:Interleukin-6; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; D004744:Enkephalin, Methionine; D009020:Morphine; D007371:Interferon-gamma